Michael W. Lu

5.1k total citations · 2 hit papers
18 papers, 3.7k citations indexed

About

Michael W. Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michael W. Lu has authored 18 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michael W. Lu's work include HER2/EGFR in Cancer Research (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Michael W. Lu is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Cancer Genomics and Diagnostics (4 papers). Michael W. Lu collaborates with scholars based in United States, Switzerland and France. Michael W. Lu's co-authors include Ian E. Krop, Ellie Guardino, Do‐Youn Oh, Luca Gianni, Véronique Dièras, Steven R. Olsen, Mark D. Pegram, Sunil Verma, David Miles and Fang Ting Liang and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Michael W. Lu

18 papers receiving 3.6k citations

Hit Papers

Trastuzumab Emtansine for HER2-Positive Advanced Breast C... 2012 2026 2016 2021 2012 2021 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    2012 2.7k citations Sunil Verma, David Miles et al. New England Journal of Medicine profile →
  2. Evaluating eligibility criteria of oncology trials using real-world data and AI
    2021 184 citations Ruishan Liu, Shemra Rizzo et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael W. Lu United States 14 2.9k 1.6k 1.0k 675 530 18 3.7k
Ellie Guardino United States 17 3.9k 1.4× 2.2k 1.4× 1.3k 1.2× 860 1.3× 619 1.2× 30 4.7k
Adam Knott United Kingdom 17 3.2k 1.1× 1.4k 0.9× 984 1.0× 843 1.2× 1.0k 1.9× 33 4.2k
Steven Stein United States 11 3.0k 1.1× 1.0k 0.6× 1.2k 1.2× 859 1.3× 762 1.4× 21 3.7k
Alexey Manikhas Russia 23 3.1k 1.1× 763 0.5× 1.4k 1.3× 880 1.3× 1.4k 2.6× 89 3.9k
José Luiz Pedrini Brazil 16 4.2k 1.5× 1.6k 1.0× 1.5k 1.4× 699 1.0× 1.8k 3.4× 28 5.0k
Emma Clark United Kingdom 20 5.1k 1.8× 2.1k 1.3× 1.7k 1.7× 1.2k 1.8× 1.6k 3.0× 50 6.2k
Laslo Roman Russia 14 4.4k 1.5× 1.4k 0.9× 1.3k 1.3× 831 1.2× 1.4k 2.7× 31 5.2k
Zefei Jiang China 30 2.5k 0.9× 744 0.5× 1.2k 1.2× 1.1k 1.7× 915 1.7× 198 3.8k
Deborah Lindquist United States 10 2.5k 0.9× 812 0.5× 938 0.9× 655 1.0× 648 1.2× 22 3.0k
Agnieszka Jagiełło-Gruszfeld Poland 13 3.4k 1.2× 881 0.6× 2.4k 2.3× 1.9k 2.8× 1.3k 2.5× 60 5.4k

Countries citing papers authored by Michael W. Lu

Since Specialization
Citations

This map shows the geographic impact of Michael W. Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Lu more than expected).

Fields of papers citing papers by Michael W. Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Lu. The network helps show where Michael W. Lu may publish in the future.

Co-authorship network of co-authors of Michael W. Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Lu. A scholar is included among the top collaborators of Michael W. Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Lu. Michael W. Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lu, Michael W., et al.. (2023). The impact of a novel musculoskeletal consult service in an inpatient rehabilitation facility: A descriptive analysis. PM&R. 16(7). 707–714. 1 indexed citations
2.
Ton, Thanh G.N., Navdeep Pal, Huong Trinh, et al.. (2022). Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data. Clinical Cancer Research. 28(13). 2844–2853. 13 indexed citations
3.
Liu, Ruishan, Shemra Rizzo, Samuel Whipple, et al.. (2021). Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 592(7855). 629–633. 184 indexed citations breakdown →
4.
Lu, Michael W., Katja Schulze, Michelle Y. Doral, et al.. (2020). A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS2087–TPS2087. 2 indexed citations
5.
Carrigan, Gillis, Samuel Whipple, William B. Capra, et al.. (2019). Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials. Clinical Pharmacology & Therapeutics. 107(2). 369–377. 72 indexed citations
6.
Lu, Michael W., et al.. (2019). Incidental Cryptococcal lung mass in an immunocompetent patient. Journal of Community Hospital Internal Medicine Perspectives. 9(5). 450–452. 1 indexed citations
7.
Lu, Michael W., Natalia Sadetsky, Peter Lambert, et al.. (2018). Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.. Journal of Clinical Oncology. 36(15_suppl). 6578–6578. 1 indexed citations
8.
Peters, Solange, Rolf A. Stahel, Lukas Bubendorf, et al.. (2018). Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clinical Cancer Research. 25(1). 64–72. 173 indexed citations
9.
Stahel, Rolf A., Lukas Bubendorf, Philip Bonomi, et al.. (2017). Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 35(15_suppl). 8509–8509. 25 indexed citations
10.
Li, Chunze, Bei Wang, Dan Lu, et al.. (2016). Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 78(3). 547–558. 14 indexed citations
11.
Verma, Sunil, David Miles, Luca Gianni, et al.. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 367(19). 1783–1791. 2665 indexed citations breakdown →
12.
13.
Beeram, Muralidhar, Ian E. Krop, Howard A. Burris, et al.. (2012). A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. Cancer. 118(23). 5733–5740. 74 indexed citations
14.
15.
16.
Dennis, Elizabeth R., Marc R. Bussière, Andrzej Niemierko, et al.. (2012). A Comparison of Critical Structure Dose and Toxicity Risks in Patients with Low Grade Gliomas Treated with IMRT versus Proton Radiation Therapy. Technology in Cancer Research & Treatment. 12(1). 1–9. 56 indexed citations
17.
Kaul, Sanjeev, et al.. (2010). Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. American Journal of Health-System Pharmacy. 67(3). 217–222. 13 indexed citations
18.
Kovarik, John M., et al.. (2008). The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. European Journal of Clinical Pharmacology. 64(5). 457–463. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellie Guardino Breakdown of academic impact, for papers by Adam Knott Breakdown of academic impact, for papers by Steven Stein Breakdown of academic impact, for papers by Alexey Manikhas Breakdown of academic impact, for papers by José Luiz Pedrini Breakdown of academic impact, for papers by Emma Clark Breakdown of academic impact, for papers by Laslo Roman Breakdown of academic impact, for papers by Zefei Jiang Breakdown of academic impact, for papers by Deborah Lindquist Breakdown of academic impact, for papers by Agnieszka Jagiełło-Gruszfeld
Rankless by CCL
2026